BACKGROUND Light chain (AL) and transthyretin (ATTR) cardiac amyloidosis (CA) cause restrictive cardiomyopathy with progressive heart failure (HF). Although anemia is a common comorbidity in HF, associated with adverse outcomes, the prevalence, incidence, and outcomes of anemia associated with CA remain poorly understood. METHODS AND RESULTS We performed a retrospective cohort study of patients seen and followed in a dedicated Cardiac Amyloidosis Clinic between January 2010 and May 2022.
